Synthetic inhibitors of endopeptidase EC 3.4.24.15: Potency and stability in vitro and in vivo

British Journal of Pharmacology

Volumn 118, Issue 5, 1996, Pages 1269-1277

  Lew, R A ^a   Tomoda, F ^a,b   Evans, R G ^a,c   Lakat, L ^a   Boublik, J H ^a   Pipolo, L A ^a   Smith, A I ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF TOYAMA   (Japan)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin; Angiotensin converting enzyme; Bradykinin; Metalloendopeptidase 24.15; Neutral endopeptidase; Pharmacokinetics; Phosphoramidon

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODINE 125; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE INHIBITOR; N (1 CARBOXY 3 PHENYLPROPYL)PHENYLALANYLISOSERINE; PHOSPHORAMIDON;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; KIDNEY; METABOLISM; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; RABBIT; STRUCTURE ACTIVITY RELATION;

EID: 0030018193     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15533.x     Document Type: Article

References (31)

1. AUSTRALIAN CODE OF PRACTICE FOR THE CARE AND USE OF ANIMALS FOR SCIENTIFIC PURPOSES. (1990). Canberra, Australia: Australian Government Publishing Service.
2. BARRETT, A.J., BROWN, M.A., DANDO, P.M., KNIGHT, C.G., MCKIE, N., RAWLINGS, N.D. & SERIZAWA, A. (1995). Thimet oligopeptidase and oligopeptidase M or neurolysin. Methods Enzymol., 248, 529-556.
3. CARDOZO, C. & ORLOWSKI, M. (1993). Evidence that enzymatic conversion of N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin converting enzyme. Peptides, 14, 1259-1262.
4. CHARLES, C.J., ESPINER, E.A., RICHARDS, A.M. & SYBERTZ, E.J. (1995). Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep. Hypertension, 26, 89-94.
5. CHU, T.G. & ORLOWSKI, M. (1984). Active site directed N-carboxymethyl peptide inhibitors of a soluble metalloendopeptidase from rat brain. Biochemistry, 23, 3598-3603.
6. CHU, T.G. & ORLOWSKI, M. (1985). Soluble metalloendopeptidase from rat brain: action on enkephalin-containing peptides and other bioactive peptides. Endocrinology, 116, 1418-1425.
7. GENDEN, E.M. & MOLINEAUX, C.J. (1991). Inhibition of endopeptidase-24.15 decreases blood pressure in normotensive rats. Hypertension, 18, 360-365.
8. HERSH, L.B. & MORIHARA, K. (1986). Comparison of the subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin. J. Biol. Chem., 261, 6433-6437.
9. JIRACEK, J., YIOTAKIS, A., VINCENT, B., LECOQ. A., NICOLAOU, A., CHECLER, F. & DIVE, V. (1995). Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24.15 using combinatorial chemistry. J. Biol. Chem., 270, 21701-21706.
10. LASDUN, A. & ORLOWSKI, M. (1990). Inhibition of endopeptidase 24.15 greatly increases the release of luteinizing hormone and follicle stimulating hormone in response to luteinizing hormone/ releasing hormone. J. Pharmacol. Exp. Ther., 253, 1265-1271.
11. LASDUN, A., REZNIK, S., MOLINEAUX, C.J. & ORLOWSKI, M. (1989). Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone. J. Pharmacol. Exp. Ther., 251, 439-447.
12. LEW, R.A., HEY, N.J., TETAZ, T.J., GLUCKSMAN, M.J., ROBERTS, J.L. & SMITH, A.I. (1995). Substrate specificity differences between recombinant rat testes endopeptidase EC 3.4.24.15 and the native brain enzyme. Biochem. Biophys. Res. Commun., 209, 788-795.
13. LEW, R.A. TETAZ, T., GLUCKSMAN, M.J., ROBERTS, J.L. & SMITH, A.I. (1994). Evidence for a two-step mechanism of gonadotropin-releasing hormone (GnRH) metabolism by prolyl endopeptidase and metalloendopeptidase EC 3.24.24.15. J. Biol. Chem., 269, 12626-12632.
14. LUDBROOK, J. (1991). On making multiple comparisons in clinical and experimental pharmacology and physiology. Clin. Exp. Pharmacol. Physiol., 18, 379-392.
15. LUDBROOK, J. (1994). Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res., 28, 303-311.
16. MOLINEAUX, C.J., LASDUN, A., MICHAUD, C. & ORLOWSKI, M. (1988). Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo. J. Neurochem., 51, 624-633.
17. ORLOWSKI, M., MICHAUD, C. & CHU, T.G. (1983). A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem., 135, 81-88.
18. ORLOWSKI, M., MICHAUD, C. & MOLINEAUX, C.J. (1988). Substrate-related potent inhibitors of brain metalloendopeptidase. Biochemistry, 27, 597-602.
19. POZSGAY, M., MICHAUD, C., LIEBMAN, M & ORLOWSKI, M. (1986). Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. Biochemistry, 25, 1292 1299.
20. SALACINSKI, P.R.P., MCLEAN, C., SKYES, J.E.C., CLEMENT-JONES. V.V. & LOWRY, P.J. (1981). Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1, 3, 4, 6-tetrachloro-3α, 6α-diphenyl glycoluril (Iodogen). Anal. Biochem., 117, 136-146.
21. SCHWARTZ, J.-C., GROS, C., LECOMTE, J.-M. & BRALET, J. (1990). Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci., 47, 1279-1297.
22. 2-and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. U.S.A., 82, 1025-1029.
23. SYBERTZ, E.J., CHIU, P.J.S., VEMULAPALLI, S., PITTS, B., FOSTER, C.J., BARNETT, A. & HASLANGER, M.F. (1989). SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J. Pharmacol. Exp. Ther., 250, 624-631.
24. SYBERTZ, E.J., JR., CHIU, P.J.S., WATKINS, R.W. & VEMULAPALLI, S. (1990). Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation. J. Hypertens., 8(Suppl. 7). S161-S167.
25. TELFORD, S.E., SMITH, A.I., LEW, R.A., PERICH, R.B., MADDEN, A.C. & EVANS, R.G. (1995). Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor. Br. J. Pharmacol., 114, 1185-1192.
26. THORSETT, E.D. & WYVRATT, M.J. (1987). Inhibition of zinc peptidases that hydrolyse neuropeptides. In Neuropeptides and Their Peptidases. ed. Turner, A.J. pp. 229-292. Chichester, UK: Ellis Horwood Ltd.
27. TISLJAR, U., KNIGHT, C.G. & BARRETT, A.J. (1990). An alternative quenched fluoresence substrate for Pz-peptidase. Anal. Biochem., 186, 112-115.
28. WILKINSON, L. (1990). Syslat: The System for Statistics. Evanston, I11, USA; SYSTAT, Inc.
29. WILLIAMS, C.H., YAMAMOTO, T., WALSH, D.M. & ALLSOP, D. (1993). Endopeptidase 3.4.24.11 converts N-1-(R,S) carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme. Biochem. J., 294, 681-684.
30. YAMAMOTO, K., CHAPPELL, M.C, BROSNIHAN, K.B. & FERRARIO, C.M. (1992). In vivo metabolism of angiotensin 1 by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension, 19, 692-696.
31. YANG, X.-P., SAITOH, S., SCICLI, A.G., MASCHA, E., ORLOWSKI, M. & CARRETERO, O.A. (1994). Effects of a metalloendopeptidase-24.15 inhibitor on renal hemodynamics and function in rats. Hypertension, 23 (Suppl. I), I-235- I-239.